|
|

- an increasing amount of new drugs developed consist of biopharmaceuticals (of which most cannot be administered orally and are chemically very unstable)
- an increasing need for non-oral advanced therapeutics delivery technologies that can maintain the viability of labile therapeutic agents
- an increasing need for long time controlled delivery of water insoluble small molecular drugs
|
|